Ticagrelor Associated Heart Block: The Need for Close and Continued Monitoring
Ticagrelor is an antiplatelet agent prescribed to prevent the development of adverse cardiac events after acute coronary syndrome (ACS). According to the PLATO trial, ticagrelor is associated with ventricular pauses in the first week of treatment; however, these episodes were felt to be asymptomatic...
Saved in:
Main Authors: | Munish Sharma, Daniel A. N. Mascarenhas |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2017-01-01
|
Series: | Case Reports in Cardiology |
Online Access: | http://dx.doi.org/10.1155/2017/5074891 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Case of Atrioventricular Block Potentially Associated with Right Coronary Artery Lesion and Ticagrelor Therapy Mediated by the Increasing Adenosine Plasma Concentration
by: Xiaoye Li, et al.
Published: (2018-01-01) -
Ticagrelor-Induced Angioedema: A Rare and Unexpected Phenomenon
by: Rajeev Seecheran, et al.
Published: (2017-01-01) -
On maps: continuous, closed, perfect, and with closed graph
by: G. L. Garg, et al.
Published: (1997-01-01) -
Clinical Outcome between Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndrome and Diabetes
by: Peixun He, et al.
Published: (2021-01-01) -
Comparison of Ticagrelor and Clopidogrel in Elective Coronary Stenting: A Double Blind Randomized Clinical Trial
by: Mohammadjavad Mehdizadeh Parizi, et al.
Published: (2023-01-01)